News

The supplemental new drug application (sNDA) approval for VIIBRYD expands dosing options available to health care providers when using it to treat MDD in adult patients. The company

The company’s lead drug candidate, ImMucin, targets the less studied Signal Peptide domain of the MUC1 tumor antigen, which harbours key advantages as an anti-MM modality. ImMucin teaches

Valeant’s new offer of $173 a share, is an increase from a bid of $158 per share in cash made this February. The revised share offer, which adds

The study was designed to investigate the effect of adding ticagrelor at 60mg and 90mg to low dose aspirin on reducing the risk of CV death, heart attack

Repatha is a new investigational low-density lipoprotein cholesterol (LDL-C)-lowering medication. A total of 4,465 patients were enrolled in the trial who had completed one of 12 Phase II

The trial evaluated Praluent 150mg every two weeks compared to placebo in patients who were at high cardiovascular (CV) risk and who were receiving maximally-tolerated statin therapy with

The deal, which triggers an undisclosed upfront payment, includes the discovery and optimisation of new compounds as well as licence agreements for already existing assets developed by Evotec.

The application is based on data from an extensive head-to-head preclinical data package comparing SB2 to the originator, a head-to-head Phase I trial in healthy volunteers, and a

The company claims that SAPHRIS is the only atypical antipsychotic treatment option with a sublingual (under the tongue) formulation. The NDA is based on the results of a